Clearing Amyloid Provides Alzheimer’s Benefit, But With Risks That Need Careful Management
Sponsors Plan Extensive Education About Safety
Executive Summary
Eisai/Biogen’s lecanemab showed that reducing amyloid can slow Alzheimer’s disease progression, but prescribers will have to weigh the potential benefit versus safety risks on a patient-by-patient basis.
You may also be interested in...
Is Lecanemab Plus t-PA A Deadly Combination? One Case Study May Shed Light
A letter in the New England Journal of Medicine suggests the death of one extension trial participant treated with t-PA may have been caused by lecanemab, but a response notes fatal intracerebral hemorrhages have been seen after t-PA in certain patients in the absence of anti-amyloid drugs.
Is Lecanemab Plus t-PA A Deadly Combination? One Case Study May Shed Light
A letter in the New England Journal of Medicine suggests the death of one extension trial participant treated with t-PA may have been caused by lecanemab, but a response notes fatal intracerebral hemorrhages have been seen after t-PA in certain patients in the absence of anti-amyloid drugs.
Lilly Does Not Expect A Quick Medicare Coverage Decision For Donanemab
Donanemab may receive accelerated approval for Alzheimer’s disease in early 2023, but Lilly will not approach CMS about Medicare coverage until mid-year when it has Phase III data – and even then does not expect a quick decision.